Skip to main content

Table 1 Clinicopathologic data

From: Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers

Parameter Group Tissue (n= 84) Serum (n= 75)
T status 1 27 (32%) 31 (41%)
  2 27 (32%) 22 (29%)
  3 6 (7%) 4 (5%)
  4 24 (29%) 18 (25%)
N status 0 35 (42%) 28 (37%)
  1 21 (25%) 15 (20%)
  2 14 (17%) 10 (13%)
  3 13 (15%) 9 (12%)
  4 1 (1%) 13 (18%)
M status 0 70 (83%) 4 (5%)
  1 14 (17%) 71 (95%)
ER status Negative 25 (30%) 23 (31%)
  Positive 59 (70%) 52 (69%)
PR status Negative 45 (54%) 36 (48%)
  Positive 39 (46%) 39 (52%)
ErbB2 status Negative 62 (74%) 49 (65%)
  Positive 22 (26%) 26 (35%)
Grade 1 9 (11%) 14 (19%)
  2 32 (38%) 29 (39%)
  3 43 (51%) 32 (42%)
Stage I 24 (29%) 19 (25%)
  II 20 (24%) 14 (19%)
  III 27 (32%) 22 (29%)
  IV 13 (15%) 20 (27%)
Disease status Progressive 29 (35%) 47 (63%)
  Nonprogressive 55 (65%) 28 (37%)
  1. ErbB2 status is determined by using the Hercep test with confirmation by FISH. Disease status is determined by using the RECIST criteria.